Lp(a) 75 nmol/L — one-and-done genetic cardiac risk
Lipoprotein(a) [Lp(a)] at 75 nmol/L is meaningfully above the contemporary cardiology research threshold of ~50 nmol/L (or ~30 mg/dL) for elevated cardiovascular risk. Unlike LDL-C, ApoB, and triglycerides — all responsive to diet, exercise, and pharmacology — Lp(a) is ~80–90% determined by the LPA gene at birth and is essentially invariant across your lifespan. A reading of 75 places you in roughly the top 20% of the population for Lp(a)-driven cardiovascular risk, which adds to (does not replace) risk from your other lipid markers. This is the one cardiac biomarker the literature treats as a 'check it once and know it forever' number.
Reference ranges
| Optimal | < 30 nmol/L |
| Borderline | 30 – 50 nmol/L |
| High | 50 – 125 nmol/L |
| Very high | > 125 nmol/L |
| Mass-units conversion | ~2.5 nmol/L per mg/dL |
What this marker measures
Lp(a) is an LDL-like particle with an additional apolipoprotein(a) tail covalently linked to ApoB. The apo(a) protein has structural homology to plasminogen, which is why Lp(a) is associated with both atherosclerotic risk (LDL-like cholesterol delivery) AND prothrombotic risk (plasminogen-mimicry inhibits fibrinolysis). The size of apo(a) is determined by KIV-2 repeat copy number, encoded in the LPA gene — smaller isoforms (fewer repeats) produce more circulating Lp(a) and thus higher concentrations. This is why Lp(a) is essentially a genetic constant.
Why might it be elevated?
- ·Genetic — LPA gene KIV-2 repeat copy number determines ~85% of variance
- ·Family history of premature cardiovascular disease (often clusters with Lp(a))
- ·Niacin can reduce Lp(a) ~25% in some research, but no outcome benefit demonstrated
- ·Hormone replacement therapy in post-menopausal women modestly lowers Lp(a)
- ·Renal failure may transiently elevate Lp(a)
Why might it be low?
- ·Genetic — large apo(a) isoforms (many KIV-2 repeats) produce less Lp(a)
- ·PCSK9 inhibitors lower Lp(a) ~25% (mechanism distinct from LDL lowering)
- ·Apheresis (lipid filtration) — used in extreme familial hypercholesterolaemia
- ·Investigational antisense / siRNA agents (pelacarsen, olpasiran) reduce Lp(a) >70% in trials
FAQ
Can I lower Lp(a) with lifestyle?+
Largely no. Diet and exercise — which work for LDL, triglycerides, and HDL — barely move Lp(a). The gene determines the production rate. The literature is consistent: focus your modifiable-risk effort on ApoB and lifestyle factors, and treat Lp(a) as a static input to total cardiovascular risk.
Should I retest?+
Once is enough. Lp(a) drifts <5% over decades for most people. Retest only if a future LPA-targeted therapy becomes available and you want a baseline before treatment.
How worried should I be?+
An elevated Lp(a) is additive to your other cardiovascular risk factors — it doesn't replace them. The reasonable response is to be more aggressive about the modifiable factors (ApoB, blood pressure, glycaemia, smoking) given that Lp(a) gives you one extra fixed risk you can't reduce. Discuss with a cardiologist if Lp(a) >125 or strong family history.
This page describes biomarker research and reference ranges for self-tracking and research-context discussion only. It is not medical advice, not a diagnosis, and not a substitute for a qualified physician. Take any concerns about your health to a clinician.
Have your own panel? Read it next to the standard reference ranges with our free analyse tool.
Analyse my blood work →